nach oben

Erschienen in:

01.07.2011 | Original Paper

Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine

verfasst von: Clifford L. Cua, Lynette K. Rogers, Louis G. Chicoine, Molly Augustine, Yi Jin, Patricia L. Nash, Leif D. Nelin

Erschienen in: European Journal of Pediatrics | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Down syndrome (DS) patients have an increased risk of developing pulmonary hypertension (PH). Increased plasma levels of asymmetric dimethylarginine (ADMA) may contribute to vascular dysfunction in adults with idiopathic pulmonary hypertension. Our goal was to test the hypothesis that DS patients with PH have higher plasma levels of ADMA than DS patients without PH. DS patients with definitive PH (n = 6) and DS patients with no evidence of PH (n = 12) were studied. Plasma levels of arginine, ADMA, and nitrite/nitrate (NOx; stable metabolites of nitric oxide (NO)) were measured. Plasma arginine concentration was lower (p < 0.05) in PH patients (23 ± 11 μM) versus non-PH patients (46 ± 24 μM). Plasma ADMA concentration was higher (p < 0.005) in PH patients (18.0 ± 4.2 μM) versus non-PH patients (8.6 ± 5.9 μM). Plasma NOx was lower (p < 0.05) in PH patients (4.5 ± 1.7 μM) versus non-PH patients (8.5 ± 7.3 μM). These results are consistent with ADMA contributing to lower NO production in DS patients with PH and suggest that ADMA levels may be a potential biomarker for PH in DS patients.

(2009) Proceedings of the 4th World Symposium on Pulmonary Hypertension, February 2008, Dana Point, California, USA. J Am Coll Cardiol 54:S1–117

Beyer J, Kolditz M, Ewert R, Rubens C, Opitz C, Schellong S, Hoeffken G, Halank M (2008) L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertension. Vasa 37:61–67PubMedCrossRef

Boger RH, Mugge A, Bode-Boger SM, Heinzel D, Hoper MM, Frolich JC (1996) Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Int J Clin Pharmacol Ther 34:323–328PubMed

Clapp S, Perry BL, Farooki ZQ, Jackson WL, Karpawich PP, Hakimi M, Arciniegas E, Green EW, Pinsky WW (1990) Down’s syndrome, complete atrioventricular canal, and pulmonary vascular obstructive disease. J Thorac Cardiovasc Surg 100:115–121PubMed

Cooney TP, Thurlbeck WM (1982) Pulmonary hypoplasia in Down’s syndrome. N Engl J Med 307:1170–1173PubMedCrossRef

Cua CL, Cooke G, Taylor M, Hayes J, Waldon L, Lipowski P, Kossman B, Nash PL (2006) Endothelial nitric oxide synthase polymorphisms associated with abnormal nitric oxide production are not over-represented in children with Down syndrome. Congenit Heart Dis 1:169–174PubMedCrossRef

Cua CL, Blankenship A, North AL, Hayes J, Nelin LD (2007) Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol 28:250–254PubMedCrossRef

Dimitroulas T, Giannakoulas G, Sfetsios T, Karvounis H, Dimitroula H, Koliakos G, Settas L (2008) Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford) 47:1682–1685CrossRef

Durante W, Johnson FK, Johnson RA (2007) Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 34:906–911PubMedCrossRef

10.

Fukushima H, Kosaki K, Sato R, Yagihashi T, Gatayama R, Kodo K, Hayashi T, Nakazawa M, Tsuchihashi T, Maeda J, Kojima Y, Yamagishi H, Takahashi T (2010) Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: an imbalance in biosynthesis of thromboxane A(2) and prostacyclin. Am J Med Genet A 152A(8):1919–1924PubMedCrossRef

11.

Girard C, Fargnoli JM, Godin-Ribuot D, Dutheil V, Maitrasse B, Girardet P, Arvieux CC (1996) Inhaled nitric oxide: effects on hemodynamics, myocardial contractility, and regional blood flow in dogs with mechanically induced pulmonary artery hypertension. J Heart Lung Transplant 15:700–708PubMed

12.

Holm T, Aukrust P, Aagaard E, Ueland T, Haugstad TS, Kjekshus J, Simonsen S, Froland SS, Gullestad L, Andreassen AK (2002) Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension. Transplantation 74:1395–1400PubMedCrossRef

13.

Jin Y, Calvert TJ, Chen B, Chicoine LG, Joshi M, Bauer JA, Liu Y, Nelin LD (2010) Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia. Am J Physiol Heart Circ Physiol 298:H1518–1528PubMedCrossRef

14.

Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper MM (2005) Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 25:1414–1418PubMedCrossRef

15.

Komai H, Naito Y, Aimi Y, Kimura H (2001) Nitric oxide synthase expression in lungs of pulmonary hypertensive patients with heart disease. Cardiovasc Pathol 10:29–32PubMedCrossRef

16.

Levine OR, Simpser M (1982) Alveolar hypoventilation and cor pulmonale associated with chronic airway obstruction in infants with Down syndrome. Clin Pediatr (Phila) 21:25–29CrossRef

17.

Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C (2005) Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 67:2330–2337PubMedCrossRef

18.

Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, Fujimura T, Matsuoka H, Kimoto M, Kato S, Imaizumi T, Okuda S (2006) Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17:2176–2183PubMedCrossRef

19.

McCaffrey MJ, Bose CL, Reiter PD, Stiles AD (1995) Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. Biol Neonate 67:240–243PubMedCrossRef

20.

McCormack D (1990) Endothelium-derived relaxing factors and the human pulmonary circulation. Lung 168(Suppl):35–42PubMedCrossRef

21.

Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, Carey RM, Johns RA (2003) Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108:1493–1498PubMedCrossRef

22.

Morris CR, Poljakovic M, Lavrisha L, Machado L, Kuypers FA, Morris SM Jr (2004) Decreased arginine bioavailability and increased serum arginase activity in asthma. Am J Respir Crit Care Med 170:148–153PubMedCrossRef

23.

Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, Gladwin MT (2005) Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294:81–90PubMedCrossRef

24.

Nagaya N, Uematsu M, Oya H, Sato N, Sakamaki F, Kyotani S, Ueno K, Nakanishi N, Yamagishi M, Miyatake K (2001) Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med 163:887–891PubMed

25.

Pearson DL, Dawling S, Walsh WF, Haines JL, Christman BW, Bazyk A, Scott N, Summar ML (2001) Neonatal pulmonary hypertension—urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med 344:1832–1838PubMedCrossRef

26.

Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, Haredza P, Klepetko W, Aigner C, Fink L, Muyal JP, Weissmann N, Grimminger F, Seeger W, Schermuly RT (2005) Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 19:1175–1177PubMed

27.

Skoro-Sajer N, Mittermayer F, Panzenboeck A, Bonderman D, Sadushi R, Hitsch R, Jakowitsch J, Klepetko W, Kneussl MP, Wolzt M, Lang IM (2007) Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 176:1154–1160PubMedCrossRef

28.

Suzuki K, Yamaki S, Mimori S, Murakami Y, Mori K, Takahashi Y, Kikuchi T (2000) Pulmonary vascular disease in Down’s syndrome with complete atrioventricular septal defect. Am J Cardiol 86:434–437PubMedCrossRef

29.

Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL (2009) Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol 53:2061–2067PubMedCrossRef

30.

Weijerman ME, van Furth AM, van der Mooren MD, van Weissenbruch MM, Rammeloo L, Broers CJ, Gemke RJ (2010) Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome. Eur J Pediatr 169(10):1195–1199PubMedCrossRef

31.

Yamaki S, Yasui H, Kado H, Yonenaga K, Nakamura Y, Kikuchi T, Ajiki H, Tsunemoto M, Mohri H (1993) Pulmonary vascular disease and operative indications in complete atrioventricular canal defect in early infancy. J Thorac Cardiovasc Surg 106:398–405PubMed

Titel: Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine
verfasst von: Clifford L. Cua
Lynette K. Rogers
Louis G. Chicoine
Molly Augustine
Yi Jin
Patricia L. Nash
Leif D. Nelin
Publikationsdatum: 01.07.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Pediatrics / Ausgabe 7/2011
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-010-1361-x

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2011

Adolescent alcohol intoxication in Dutch hospital centers of pediatrics: characteristics and gender differences

Cobalamin C defect presenting as severe neonatal hyperammonemia

Attention-deficit hyperactivity disorder in children chronically exposed to high level of vehicular pollution

A case report of hyperthyroid-associated thymic hypertrophy in a child, presenting as an anterior mediastinal mass

Management of pulmonary hypertension in Down syndrome

Detection of Mycoplasma pneumoniae in different respiratory specimens

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie